Cargando…
Tamoxifen exerts anti-peritoneal fibrosis effects by inhibiting H19-activated VEGFA transcription
BACKGROUND: Peritoneal dialysis (PD) remains limited due to dialysis failure caused by peritoneal fibrosis. Tamoxifen (TAM), an inhibitor of estrogen receptor 1 (ESR1), has been reported to treat fibrosis, but the underlying mechanism remains unknown. In this study, we sought to explore whether tamo...
Autores principales: | Zhao, Tingting, Sun, Zhengyu, Lai, Xueli, Lu, Hongtao, Liu, Lulu, Li, Shuangxi, Yuan, Ji-hang, Guo, Zhiyong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494369/ https://www.ncbi.nlm.nih.gov/pubmed/37697303 http://dx.doi.org/10.1186/s12967-023-04470-3 |
Ejemplares similares
-
Tamoxifen and bone morphogenic protein-7 modulate fibrosis and inflammation in the peritoneal fibrosis model developed in uremic rats
por: Silva, Filipe M. O., et al.
Publicado: (2019) -
Advances in stem cell therapy for peritoneal fibrosis: from mechanisms to therapeutics
por: Huang, Weiyan, et al.
Publicado: (2023) -
Tamoxifen attenuates dialysate-induced peritoneal fibrosis by inhibiting GSK-3β/β-catenin axis activation
por: Yan, Pengpeng, et al.
Publicado: (2018) -
Tamoxifen Ameliorates Peritoneal Membrane Damage by Blocking Mesothelial to Mesenchymal Transition in Peritoneal Dialysis
por: Loureiro, Jesús, et al.
Publicado: (2013) -
Omental adipocytes promote peritoneal metastasis of gastric cancer through the CXCL2–VEGFA axis
por: Natsume, Makoto, et al.
Publicado: (2020)